Replimune more than doubles after FDA panel backs skin cancer drug

Replimune

31/07/2026 15:13

Updates
** Shares of drug developer Replimune REPL.O jumped 127% to $12.32
** Shares touched a 52-week high of $12.50 earlier in the session; on track for their best day on record, if gains hold
** US FDA panel of outside advisers on Thursday voted to back results from a trial studying REPL drug for a type of skin cancer
** REPL seeks accelerated approval for RP1 in combination with Bristol Myers Squibb's BMY.N Opdivo for advanced melanoma in patients whose tumors grew despite prior treatment; decision expected by August 2
** "Given the media attention surrounding this decision, we think it's a near certainty that the FDA follows the panel's advice" - Cantor Fitzgerald 
** Brokerage assumes unadjusted peak U.S. sales of $708 million by 2040 for RP1
** Shares have surged more than 700% from 52-week low of $1.50 in April 2026
** More than 10.2 mln shares traded, about 2.3 times the stock's 30-day average volume
** Including session's move, stock up 27% YTD 

 (Reporting by Sneha S K and Kamal Choudhury)
 ((Sneha.SK@thomsonreuters.com;))